Mounjaro Payment Plans in the UK: How the Costs Actually Work

Step 1, Understand why Mounjaro cannot be offered on a traditional payment plan

Mounjaro is a Prescription-Only Medicine (POM) under the Human Medicines Regulations 2012. That classification shapes everything about how it is sold. A pharmacy cannot list it like a retail product, run promotional finance deals tied to the medicine, or bundle it into a subscription that auto-dispatches without fresh clinical oversight. Each order requires a prescription, and each prescription follows a clinical assessment.

That is not a technicality. It is the framework that keeps the supply chain safe. The NHS's patient guidance on tirzepatide makes clear that treatment should only begin under supervision, with regular review. Any service that appears to sidestep that, whether through an automatic monthly box or a checkout-style finance plan with no clinical gate, is worth scrutinising carefully.

In practice, this means the phrase "Mounjaro payment plan" usually refers to one of two things: providers that offer a third-party buy-now-pay-later option (such as Klarna) at checkout, or month-by-month pricing that lets you pay as you go rather than upfront for a longer course. If you want a full breakdown of what those structures look like in practice, our page on Mounjaro payment plans covers both options in detail. Both are legitimate if the clinical review happens before each order. Neither removes the prescription requirement.

Step 2, Know what third-party finance options like Klarna actually involve

Some private clinics and pharmacies have integrated Klarna or similar services into their checkout. If you are considering that route, it is worth understanding what you are agreeing to. Buy-now-pay-later products are regulated by the Financial Conduct Authority, not the MHRA, and carry their own credit terms, interest structures and late-payment consequences.

A question our prescribers hear most weeks is whether spreading the cost over three months makes the treatment cheaper in total. Usually it does not: the medicine price stays the same, and depending on the provider, interest or fees may be added. The convenience of deferred payment is real, but the arithmetic is worth checking before you click through. If you want to explore how Klarna payment works alongside a Mounjaro prescription in more detail, our page on Mounjaro and Klarna covers the practicalities.

One further practical point: if your dose increases mid-course, your per-pen cost may change. A finance agreement made at your starting dose may not reflect what you spend at 7.5mg or 10mg. Plan for that flexibility.

Step 3, Compare pay-as-you-go monthly costs against what they include

The most common structure among regulated UK providers is monthly pricing, paid at each repeat order. Eli Lilly raised Mounjaro's UK list price from September 2025; as widely reported, the highest-dose pen's list price rose to around £330, and typical private prices across providers have ranged roughly £149–£375 per month depending on dose and what the service includes. Those figures give you a fair market context, though they shift.

What matters as much as the headline number is what sits inside it. Some providers charge separately for the consultation, the prescription, and the delivery. Others, including services that publish a single transparent price, bundle everything: clinical review, the prescription, and tracked next-working-day delivery. When you compare monthly costs, compare the full picture rather than the pen price alone.

The NICE appraisal of tirzepatide (TA1026) outlines the clinical context for treatment and the criteria under which it is recommended on the NHS. Reading that alongside private pricing helps you weigh both routes with clearer information.

Step 4, Consider whether NHS access applies to you before committing to private costs

NHS access to tirzepatide is rolling out in phases. As of June 2026, adults with a BMI of 40 or above and four or more qualifying weight-related conditions (which include type 2 diabetes, high blood pressure, dyslipidaemia, cardiovascular disease and obstructive sleep apnoea) can be referred. A second cohort covering BMI 35–39.9 with four or more conditions became eligible from 23 June 2026. Further cohorts are planned through 2027. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

If you do not meet those criteria yet, or if your GP practice is not participating in the new prescribing pathway, private treatment through a regulated pharmacy is the practical alternative. There is no waiting list and no referral needed, but there is still a clinical assessment, that part does not change. You can read more about tirzepatide and how private treatment works, or explore the broader range of weight-loss treatment options to see what fits your circumstances.

If you have questions about whether Mounjaro is clinically appropriate for you, or conditions that might affect suitability, our guide to who Mounjaro may not be suitable for is a good starting point before you consult a prescriber. When you are ready, checking your eligibility and understanding your Mounjaro plan with our team is free and takes a few minutes.